



LOW-DOSE PULSE CYCLOPHOSPHAMIDE THERAPY AS A TREATMENT FOR REFRACTORY AUTOIMMUNE HEMOLYTIC ANEMIA: A PROSPECTIVE STUDY

Dr. Saritha Suryadevara^{1*}, Dr. Nagachakravarthy Mareedu²

¹Assistant Professor, Department of General Medicine, Arunai Medical College and Hospital Velu Nagar, Mathur, Tiruvannamalai – 606 603, Tamilnadu, India.

²Assistant Professor, Department of General Medicine, Prathima Relief Institute of Medical Sciences, Nagunur, Karimnagar-505417, India.

ABSTRACT

Autoimmune hemolytic anemia (AIHA) is a rare disorder characterized by the destruction of red blood cells caused by autoantibodies. Managing severe, refractory AIHA is particularly challenging for patients who do not respond to steroids or other immunosuppressive treatments. This study investigates the effectiveness of low-dose pulse cyclophosphamide therapy (1g/month for four months) as an alternative to splenectomy and rituximab. A total of 34 patients (20 males and 14 females) aged 21 to 53 years were included in the study. Significant improvements were observed, with hemoglobin levels rising and reticulocyte counts decreasing after treatment. By the fourth cycle, 83% of patients achieved partial remission (PR), and 42% maintained hemoglobin levels ≥ 10 g/dL without the need for transfusion. Six months after completing the treatment, complete remission (CR) was seen in several patients. No major adverse effects were noted during the study. These results suggest that low-dose pulse cyclophosphamide could be a promising, cost-effective treatment option for refractory AIHA, and further large-scale studies are recommended to validate these findings.

Keywords: - Autoimmune hemolytic anemia, Low-dose pulse cyclophosphamide, Refractory AIHA, Partial remission, Treatment efficacy

Access this article online		
Home Page: www.mcmed.us/journal/abs	Quick Response code 	
Received:25.10.2019	Revised:12.11.2019	Accepted:15.12.2019

INTRODUCTION

Autoimmune hemolytic anemia (AIHA) is a rare disorder, with a population-based study estimating an incidence of 0.8 per 10,000 individuals and a prevalence of 17 per 1,000 [1]. Primary (idiopathic) AIHA is less common, whereas secondary AIHA necessitates the identification and management of underlying conditions [2]. Laboratory investigations remain the cornerstone for diagnosis, with substantial advancements in diagnostic techniques. AIHA is generally characterized by decreased haptoglobin levels, elevated lactate dehydrogenase (LDH) levels, and broad-spectrum

antibodies targeting immunoglobulins and complement. However, in secondary AIHA cases, certain characteristic laboratory findings may be absent [3]. Various factors, such as disease onset, recent infections, previous blood transfusions, vaccinations, and signs of immune disorders (e.g., arthritis), help in diagnosing secondary AIHA. A critical aspect is ruling out drug-induced hemolytic anemia, as discontinuing the causative medication is often the most effective treatment strategy. Clinical history, physical examination, and antibody profiles guide further diagnostic investigations, with procedures

such as abdominal computed tomography, immunoglobulin level assessment, lupus anticoagulant testing (if warm antibodies are detected), and bone marrow analysis being relevant for treatment decisions [4].

Most AIHA cases respond to glucocorticoid therapy, although relapses are common. For patients refractory to steroids or unresponsive to other treatments, splenectomy is often considered as a second-line intervention [5]. Other immunomodulatory agents, including intravenous immunoglobulin, danazol [6], cyclophosphamide, azathioprine, cyclosporine, and vincristine (at minimal doses), are used as salvage therapies. Rituximab, administered at 375 mg/m² on days 1, 8, 15, and 22, is another second-line option, offering short-term benefits for patients who are either ineligible for or unwilling to undergo splenectomy. However, due to limited patient selection, the heterogeneity of study populations, and a lack of long-term safety and efficacy data, its broader applicability remains uncertain. In cases where complete remission (CR) is achieved with rituximab, splenectomy may be delayed or avoided [7]. Both azathioprine and cyclophosphamide function as immunosuppressants, reducing autoantibody production. For steroid-resistant patients, maintenance doses exceeding 20 mg/day or steroid tapering should be considered.

Cyclophosphamide (100 mg/day) or azathioprine may be used alone or in combination with steroids. Due to their myelosuppressive effects, regular peripheral blood cell monitoring is necessary, with dose adjustments as required. Prior to the introduction of rituximab, azathioprine and cyclophosphamide were frequently employed as second-line treatments; however, their use has decreased due to limited effectiveness and associated adverse effects [4]. Long-term steroid therapy often leads to resistance, complicating the treatment of AIHA. High-dose cyclophosphamide therapy has been explored in AIHA patients unresponsive to conventional treatments [8]. Pulse cyclophosphamide therapy has proven effective in managing lupus nephritis in systemic lupus erythematosus [9]. This regimen suppresses both T and B lymphocytes in autoimmune diseases, thereby reducing autoantibody production [10]. Cyclophosphamide is also a potent immunosuppressive agent in allogeneic bone marrow transplantation [11]. Cyclophosphamide-resistant lymphocytes contain aldehyde dehydrogenase, which protects them from the drug's cytotoxic effects [12]. In severe aplastic anemia, high-dose cyclophosphamide has induced long-term remission without requiring continued treatment [13]. This approach has also been effective in treating other autoimmune diseases [14] and in eliminating alloantibodies [15]. This study evaluates the use of pulse cyclophosphamide (1g/month for four months) as a

treatment option for patients with severe refractory AIHA unresponsive to steroids.

METHODOLOGY

A prospective study was conducted wherein intravenous pulse cyclophosphamide (1 gram/month) was administered to individuals with severe refractory warm autoimmune hemolytic anemia (AIHA) who had not responded to conventional treatments such as steroids, azathioprine, intravenous immunoglobulin, and oral cyclophosphamide. These patients were unable to reduce their prednisone dosage below 10 mg/day. For patients with suspected secondary AIHA, the diagnosis of warm AIHA was established based on clinical symptoms, physical examinations, and a comprehensive blood profile, which included reticulocyte count, direct antiglobulin test (DAT) positivity, unconjugated hyperbilirubinemia, elevated lactate dehydrogenase (LDH), antinuclear factor (ANF), and anti-double-stranded DNA (anti-dsDNA) antibodies. Before obtaining verbal consent, participants were informed about the study objectives and methodology and were invited to enroll. Monthly laboratory evaluations were performed, which included complete blood counts, DAT levels, bilirubin levels, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) levels.

The treatment response was classified as follows:

- Complete Response (CR): Hemoglobin (Hb) \geq 12 g/dL
- Partial Response (PR): Hemoglobin (Hb) \geq 10 g/dL or an increase in Hb by at least 2 g/dL
- No Response (NR): Failure to meet the criteria for either CR or PR.

STATISTICS

Statistical analysis was conducted using the SPSS software, with a significance threshold set at $P < 0.05$.

RESULTS

This study comprised 20 males and 14 females, ranging in age from 21 to 53 years (average: 35.52×10). Among them, 26 individuals were diagnosed with primary warm AIHA, while four female participants had secondary warm AIHA. Over the past year, patients who received packed RBC transfusions had baseline hemoglobin levels (g/dL) and reticulocyte counts (%) of 6.6 ± 2.6 and 14.23 ± 8.29 , respectively, before initiating cyclophosphamide therapy. During four consecutive months of pulse cyclophosphamide treatment (1 g/month), hemoglobin levels (g/dL), direct antiglobulin test (DAT) results, and reticulocyte counts were monitored. By the completion of the fourth cyclophosphamide cycle, 83% of patients exhibited a partial response (PR), while 26 experienced no response

(NR). Seven patients (42%) achieved hemoglobin levels of at least 10 g/dL without requiring a blood transfusion, whereas 16 (48%) were able to maintain a prednisone dosage of less than 10 mg/day without transfusion support. Additionally, 4 patients (12.7%) had hemoglobin values ranging between 8 and 8.4 g/dL. Six months post-cyclophosphamide treatment, complete remission (CR) was observed, with patients sustaining prednisone doses below 10 mg/day and achieving transfusion independence (Table 1). Hemoglobin levels significantly

increased after the first, second, third, and fourth months of cyclophosphamide therapy, while reticulocyte percentages showed a notable decline. Hemoglobin levels progressively rose after each cyclophosphamide cycle, reaching their peak by the fourth cycle (Table 2). Similarly, the reticulocyte count (%) continued to drop significantly following each cycle, eventually reaching its lowest point. Throughout the study, no abnormalities were detected in white blood cell (WBC) count, platelet count, or renal function parameters.

Table 1: Patient demographics before and after cyclophosphamide treatment.

Age (years) and Patients sex		Types of AIHAA	HB	RC	DA	HB	R	DAT	Type of	HB
Therapy prior to pulse cyclophosphamide			(g/dL)	%	T	(g/dL)	%		response	(g/dL)
21/Male	Primary	Steroids+ azathioprine	6	34	+	10.9	8	-	112	PR
31/Female	Primary	Steroids+ azathioprine	8	24	+	11.3	7	-	13.3	PR
41/Female	Secondary (SLE)	Steroids+ azathioprine Intravenous immunoglobulin + oral cyclophosphamide	10	13	+	12.2	5	-	13.7	PR
51/Female	Primary	Steroids+azathioprine+oral cyclophosphamide	4.5	15	+	11.7	7	-	PR	14
31/Male	Primary	Steroids+azathioprine	7.3	13	+	10.7	7	+	PR	11.8
32/Male	Primary	Steroids+oral cyclophosphamide	6.3	24	+	11.2	8		PR	12.5
24/Female	Primary	Steroids + azathioprine + Intravenous immunoglobulin + oral cyclophosphamide	5.7	19	+	10.4	6	+	PR	13.3
36/Male	Primary	Steroids+ azathioprine	7.8	15	+	10	5	+	PR	11.5
23/Female	Secondary (SLE)	Steroids+ azathioprine + oral cyclophosphamide	5.5	8	+	11.2	5		PR	13.3
47/Male	Primary	Steroids + azathioprine	5.6	9	+	9.9	6	+	PR	10.2
53/Male	Primary	Steroids + azathioprine	8.3	8	+	10.3	5	-	NR	12.2
44/Female	Secondary (SLE)	Steroids+ azathioprine + oral cyclophosphamide	7.4	8	+	11.6	7	-	PR	13.6
45/Male	Primary	Steroids + azathioprine + oral cyclophosphamide	9.3	13	+	10.4	8	-	NR	14.3
28/Female	Secondary (SLE)	Steroids + azathioprine + oral cyclophosphamide	6.7	9	+	10.3	7	-	PR	13
36/Male	Primary	Steroids + azathioprine	7.2	13	+	10	7	+	PR	12.1
35/Male	Primary	Steroids + azathioprine	9.3	9	+	10	7	+	NR	13.9
34/Male	Primary	Steroids + azathioprine	5.5	8	+	8.4	7	+	PR	10

Table 2: Hemoglobin levels before and after cyclophosphamide treatment at 1, 2, 3 and 4 months.

Hemoglobin level (g/dL)	P value
Prior to cyclophosphamide therapy (6.6 ± 2.6) vs.	
After 1 month	**
2 months later	***
3 months later	***
4 months later	***
One month later (8.1 ± 2.2) vs.	
Two months later	**
3 months later	***
4 months later	***
Two months later (9.1 ± 0.9) vs.	
Three months later	**
Four months later	***
Three months later (9.8 ± 0.9) vs.	
After 4 months (10.6 ± 0.10)	**

DISCUSSION

Managing patients with severe autoimmune hemolytic anemia (AIHA) that is resistant to steroids presents significant challenges, particularly when individuals are unable to tolerate the maximum steroid dose or reject adjunct therapies such as azathioprine, intravenous immunoglobulin, or cyclophosphamide. Additionally, patients often prefer to avoid surgical interventions like splenectomy, while the limited availability of compatible blood products, including washed red blood cells, and financial restrictions imposed by healthcare funding authorities further complicate treatment. Our study demonstrated promising outcomes with pulse cyclophosphamide therapy, showing no detectable risks. AIHA typically has an acute onset but is generally considered a chronic condition. Long-term remission or cure rates for primary AIHA remain low, making symptom management and the prevention of "hemolytic crises" the primary treatment goals while minimizing both short- and long-term adverse effects. Surprisingly, AIHA management continues to be largely based on clinical experience rather than standardized protocols, which is an unfortunate reality. Although some phase 2 prospective studies exist, no randomized trials have been conducted. Furthermore, there is no universally accepted definition for partial remission (PR) or complete remission (CR). The optimal treatment approach for AIHA patients who fail corticosteroid therapy and for whom splenectomy is not an option remains uncertain. These patients are often treated with a combination of low-dose cytotoxic therapies, danazol, and intravenous immunoglobulins. However, many individuals exhibit only partial responsiveness to these treatments and continue to require glucocorticoids. Despite ongoing research, treatment advancements have been slow, and no definitive guidelines have been established. For AIHA patients who do not respond to

glucocorticoids, splenectomy remains the primary second-line treatment. However, in cases of secondary AIHA, splenectomy has a lower success rate and is associated with increased complications. The efficacy and safety of rituximab for AIHA remain uncertain, and its use requires repeated administration every 1–3 years, heightening the risk of infections, including progressive multifocal leukoencephalopathy. The selection of second-line treatment for warm AIHA (WAIHA) patients is largely influenced by the clinician's expertise, patient's age, comorbidities, drug availability, cost, and individual preferences. Safety is the key consideration in choosing any medication, as no existing treatment has a high cure rate, and the risks associated with therapy may outweigh the benefits. In clinical practice, hematologists engage in detailed discussions with patients to make personalized treatment decisions. Previous studies have supported the efficacy of cyclophosphamide in treating AIHA, although they lacked specific patient data. Further research is needed to explore this therapeutic approach for refractory AIHA. Our study yielded results similar to those of a previous study [8] but with a lower dose and without the use of mesna. Unlike high-dose cyclophosphamide, our patients did not experience transient alopecia, nausea, vomiting, or neutropenia. To further validate these findings, a comparative study involving a larger patient population and different cyclophosphamide regimens is recommended.

CONCLUSION

For patients with severe refractory AIHA, low-dose pulse cyclophosphamide has shown effectiveness in inducing remission, offering a viable alternative to splenectomy and the associated risks, as well as to rituximab, which comes with higher costs. However, a larger patient cohort would be required to thoroughly

evaluate the efficacy and feasibility of this treatment approach.

REFERENCES

1. Dhaliwal G, Cornett PA, Tierney LM *et al.* Hemolytic anemia. *Am Fam Physician* 69, 2004, 2599–2606.
2. Golding JS. The bone changes in sickle cell anaemia. *Ann R Coll Surg Engl* 19, 1956, 296–315.
3. Salama OS, Al-Tonbary YA, Shahin RA, Eldeen OAS. Unbalanced bone turnover in children with beta-thalassemia. *Hematology* 11, 2006, 197–202.
4. Lal A, Fung EB, Pakbaz Z, Hackney-Stephens E, Vichinsky EP *et al.* Bone mineral density in children with sickle cell anemia. 2006, 901–906.
5. Perisano C, Marzetti E, Spinelli MS, Calla` CAM, Graci C *et al.* Physiopathology of bone modifications in β -thalassemia. *Anemia* 2012, 320737.
6. Voskaridou E, Terpos E *et al.* Bone disease in haemoglobin disorders. 3, 2013, 55–58.
7. Moreau R, Tshikudi Malu D, Dumais M, Dalko E, Gaudreault V *et al.* Alterations in bone and erythropoiesis in hemolytic anemia: comparative study in bled, phenylhydrazine-treated and Plasmodium-infected mice. *PLoS One* 7, 2012, e46101.
8. Nourai M, Cheng K, Niu X, Moore-King E, Fadojutimi-Akinsi MF *et al.* Predictors of osteoclast activity in patients with sickle cell disease. *Haematologica* 96, 2011, 1092–1098.
9. Morabito N, Gaudio A, Lasco A, Atteritano M, Pizzoleo MA *et al.* Osteoprotegerin and RANKL in the pathogenesis of thalassemia-induced osteoporosis: new pieces of the puzzle. *J Bone Miner Res* 19, 2004, 722–727.
10. Voskaridou E. Osteoporosis and osteosclerosis in sickle cell/ β -thalassemia: the role of the RANKL/osteoprotegerin axis. *Haematologica* 91, 2006, 813–816.
11. Goodman B, Artz N, Radford B, Chen IA. Prevalence of vitamin D deficiency in adults with sickle cell disease. *PubMed Commons* 2010, 20437740.
12. Buisson AM, Kawchak DA, Schall JI, Ohene-Frempong K, Stallings VA *et al.* Bone area and bone mineral content deficits in children with sickle cell disease. *Pediatrics* 116, 2005, 943–949.
13. Guntur AR, Rosen CJ *et al.* IGF-1 regulation of key signaling pathways in bone. *Bonekey Rep* 2, 2013, 437.
14. Soliman AT, Bererhi H, Darwish A, Alzalabani MM, Wali Y *et al.* Decreased bone mineral density in prepubertal children with sickle cell disease: correlation with growth parameters, degree of siderosis and secretion of growth factors. *J Trop Pediatr* 44, 1998, 194–198.
15. Mahachoklertwattana P, Chuansumrit A, Sirisriro R, Choubtum L, Sriphrapadang A *et al.* Bone mineral density, biochemical and hormonal profiles in suboptimally treated children and adolescents with beta-thalassemia disease. *Clin Endocrinol (Oxf)* 58, 2003, 273–279.
16. Sarrai M, Duroseau H, D'Augustine J, Moktan S, Bellevue R *et al.* Bone mass density in adults with sickle cell disease. *Br J Haematol* 136, 2007, 666–672.
17. Osunkwo I, Hodgman EI, Cherry K, Dampier C, Eckman J *et al.* Vitamin D deficiency and chronic pain in sickle cell disease. *Br J Haematol* 153, 2011, 538–540.

Cite this article

Dr. Saritha Suryadevara & Dr. Nagachakravarthy Mareedu. (2020). Low-Dose Pulse Cyclophosphamide Therapy as a Treatment for Refractory Autoimmune Hemolytic Anemia: A Prospective Study. *Acta Biomedica Scientia*. 7(2), 317-321



Attribution-NonCommercial-NoDerivatives 4.0 International